Benchmark Reiterates “Buy” Rating for Omnicell (NASDAQ:OMCL)

Omnicell (NASDAQ:OMCL)‘s stock had its “buy” rating reaffirmed by equities researchers at Benchmark in a research note issued on Wednesday, Benzinga reports. They presently have a $48.00 price target on the stock. Benchmark’s price target suggests a potential upside of 13.96% from the stock’s previous close.

OMCL has been the topic of a number of other reports. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, September 19th. JPMorgan Chase & Co. raised their price target on shares of Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research note on Friday, August 23rd. Wells Fargo & Company raised their price target on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a research note on Friday, August 2nd. Bank of America raised their price target on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $26.00 to $39.00 in a research note on Friday, August 2nd. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Omnicell has an average rating of “Moderate Buy” and an average price target of $39.50.

Omnicell Trading Down 1.9 %

OMCL stock opened at $42.12 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.22 and a current ratio of 2.45. The company’s 50-day simple moving average is $42.91 and its 200 day simple moving average is $33.62. Omnicell has a 52 week low of $25.12 and a 52 week high of $45.85. The company has a market capitalization of $1.93 billion, a PE ratio of -91.57, a price-to-earnings-growth ratio of 46.63 and a beta of 0.83.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. The business had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s revenue was down 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.29 earnings per share. As a group, sell-side analysts anticipate that Omnicell will post 0.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in OMCL. Nebula Research & Development LLC bought a new position in Omnicell during the 4th quarter worth approximately $891,000. Caxton Associates LP bought a new position in Omnicell during the 4th quarter worth approximately $2,115,000. Greenwood Capital Associates LLC raised its holdings in Omnicell by 12.9% during the 4th quarter. Greenwood Capital Associates LLC now owns 12,659 shares of the company’s stock worth $476,000 after purchasing an additional 1,447 shares during the last quarter. Vanguard Group Inc. raised its holdings in Omnicell by 8.5% during the 4th quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock worth $209,653,000 after purchasing an additional 434,336 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC bought a new position in Omnicell during the 1st quarter worth approximately $300,000. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.